Dr. Herman Weiss
Sep 20, 2026
When The Lancet published the global consensus renaming PCOS to PMOS in May, I said the name change was the starting gun, not the finish line, and this series would track whether the infrastructure underneath patient care actually moves. Part 1 covered what was real versus still on paper at three months. This past month produced the first unambiguous infrastructure move - and a few smaller ones worth noticing.
The big one: PMOS is now in the guidelines
NICE - the UK's National Institute for Health and Care Excellence, whose guidelines shape clinical practice well beyond Britain - has published a full draft guideline titled "Polyendocrine metabolic ovarian syndrome (previously known as polycystic ovary syndrome): assessment and management." Not a footnote acknowledging the rename: the term PMOS is used in the title and throughout the recommendations. The final version is expected December 9, 2026. [certain]
Two things about this matter more than the title. First, this is the stage of the 8-stage implementation roadmap that actually changes practice - guideline adoption is what turns a consensus paper into something a clinician is measured against. Second, look at what the guideline bothers to cover. Alongside cycles, androgens, and fertility, it has dedicated sections on metabolic health problems in adults, cardiovascular disease, diabetes screening, obstructive sleep apnea, endometrial cancer surveillance, depression and anxiety, and eating disorders - for everyone aged 10 and up, not just women trying to conceive. That is the entire argument of the reclassification, written into a national standard: this was never only a fertility condition, and the monitoring should never have stopped at the ovaries. [certain]
To be clear about what it isn't: it's still a draft (consultation closed in August), it's UK-only in force, and most of its recommendations adapt the 2023 Monash international guideline rather than introducing new evidence. A PDF in London doesn't change an appointment in Tel Aviv or Toledo tomorrow. But that's how these shifts actually happen - standards first, then training, then the defaults in the exam room. [likely]
The research establishment is saying it out loud
The same week, Cell Metabolism - one of the top metabolism journals, not a reproductive-medicine outlet - ran a commentary by Stener-Victorin, Zhao, Azziz, and Teede with a title that could be this series' thesis: "A new name, an old crisis: Metabolic dysfunction at the core of polyendocrine metabolic ovarian syndrome." These aren't peripheral voices: Teede led the international guideline, Azziz built much of the diagnostic framework the field has used for decades, and Stener-Victorin is one of the most-cited PCOS researchers alive. Their argument: the rename reframes "a profoundly misunderstood condition for which basic metabolic research remains critically underfunded and fragmented." [certain]
When the senior researchers who named the problem start publishing in metabolism journals rather than only in OB/GYN journals, that's the research infrastructure moving - grant categories, journal sections, and training programs follow where papers like this point. [likely]
And the clinicians are getting the memo
The American Journal of Obstetrics and Gynecology published its own primer in late August: "From PCOS to PMOS: What Obstetricians and Gynecologists Need to Know." Meanwhile, September being PCOS awareness month, mainstream outlets are running plain-language PMOS explainers. The vocabulary is spreading faster than I expected in Part 1 - though I still wouldn't bet on your own doctor saying "PMOS" this month, and that's fine. Vocabulary was never the metric; behavior is. [likely]
What's still on paper
Nothing has moved on ICD coding, billing, or EHR defaults - the stages that determine whether your chart, your insurance claim, and your screening reminders say PMOS or PCOS. Those are scheduled for the later stages of the transition plan, with full guideline integration still targeted for 2028. The honest scorecard, four months in: guidelines and research framing are moving ahead of schedule; the plumbing of daily care hasn't budged. [likely]
What I'd watch next: the NICE final publication on December 9 - the first complete national standard of care written under the PMOS name, and the template other countries' guidelines will be checked against. When it lands, I'll go through what it actually recommends for metabolic monitoring, because that's the part most likely to change what you're offered at your next visit.
Medical Disclaimer
Use of this content does not create a doctor–patient relationship. Individual responses to treatments and lifestyle changes can vary, and only your healthcare provider can evaluate your specific circumstances. If you are experiencing a medical emergency, call your local emergency services immediately.